# EDGAR Filing Document

**Accession Number:** 0001828253
**File Stem:** 0001171843-26-002009
**Filing Date:** 2026-3
**Character Count:** 9867
**Document Hash:** 706c5455dc820fc1ed937fdedfbfa2df
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-26-002009.hdr.sgml**: 20260330

**ACCESSION NUMBER**: 0001171843-26-002009

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 2

**CONFORMED PERIOD OF REPORT**: 20260330

**FILED AS OF DATE**: 20260330

**DATE AS OF CHANGE**: 20260330

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Evaxion A/S
- **CENTRAL INDEX KEY:** 0001828253
- **STANDARD INDUSTRIAL CLASSIFICATION:** BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39950
- **FILM NUMBER:** 26810041

**BUSINESS ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** DR NEERGAARDS VEJ 5F
- **CITY:** HOERSHOLM
- **PROVINCE COUNTRY:** G7
- **BUSINESS PHONE:** 4552656554

**MAIL ADDRESS:**
- **ADDRESS IS A NON US LOCATION:** YES
- **STREET 1:** DR NEERGAARDS VEJ 5F
- **CITY:** HOERSHOLM
- **PROVINCE COUNTRY:** G7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Evaxion Biotech A/S
- **DATE OF NAME CHANGE:** 20201014

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Form 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934**

**For the month of March 2026**

Commission File Number: **001-39950**

**Evaxion A/S**

(Exact Name of Registrant as Specified in Its Charter)

**Dr. Neergaards Vej 5f DK-2970 Hoersholm Denmark**

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F [ X ] &nbsp;&nbsp;&nbsp;&nbsp; Form 40-F [ ]

------

**INCORPORATION BY REFERENCE**

This report on Form 6-K shall be deemed to be incorporated by reference in Evaxion A/S's registration statements on Form S-8 (File No. 333-255064), on Form F-3 (File No. 333-265132), on Form F-1, as amended (File No. 333-266050), Form F-1 (File No. 333-276505), Form F-1 (File No. 333-279153), Form F-1 (File No. 333-283304), and Form F-3 (File No. 333- 285778), including any prospectuses forming a part of such registration statements and to be a part thereof from the date on which this report is filed, to the extent not superseded by documents or reports subsequently filed or furnished.

**Press Release**

On March 30, 2026, Evaxion A/S (the "Company"), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, issued a press release titled "Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress". A copy of the press release is furnished as Exhibit 99.1 to this report on Form 6-K.

**Exhibits** 

<u>Exhibit No.</u> <u>Description</u> <br>[99.1](exh_991.htm) [Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress](exh_991.htm)

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  |  | <u>**Evaxion A/S**</u> |
|  |  | (Registrant) |
| Date: March 30, 2026 | By: | <u>/s/ Helen Tayton-Martin&nbsp;&nbsp;&nbsp;&nbsp;</u> |
|  |  | Helen Tayton-Martin |
|  |  | Chief Executive Officer |

---

## Exhibit 99.1

**EXHIBIT 99.1**

**Evaxion to present novel AI-based polio vaccine design concepts at the World Vaccine Congress**

* **Using its pioneering AI-platform, AI-Immunology™, Evaxion has, in collaboration with the Gates Foundation, developed novel design concepts for polio vaccines potentially superior to those currently used**

* **The AI-Immunology™ concepts include hybrid capsid designs and *de novo* designed B-cell antigen approaches**

* **Despite polio vaccines being available for decades, the highly infectious viral disease continues to pose a global health risk**

* **Evaxion will also present data from its EVX-V1 vaccine program targeting cytomegalovirus at the World Vaccine Congress**

COPENHAGEN, Denmark, March 30, 2026 - Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, has in collaboration with the Gates Foundation developed novel and potentially superior concepts for design of vaccines to combat polio. These concepts, and the underlying research, will be presented at the World Vaccine Congress taking place in Washington D.C. from March 31 to April 2, 2026.

Current polio vaccines are based on inactivated or attenuated versions of the virus. While these vaccines are effective, they each have shortcomings in certain settings. Thus, it has been a long-standing - but so far unreachable - goal to create a novel polio vaccine that combines the strongest aspects of the existing vaccines.

To achieve this, Evaxion has deployed AI-Immunology™ to develop novel vaccine design concepts for a next-generation polio vaccine, which may enhance the chances of completing and sustaining polio eradication once and for all.

"These new polio vaccine design concepts are great examples of how AI-Immunology™ enables novel approaches to diseases for which adequate treatment options do not exist despite decades of research. We are excited to have applied the platform within a new viral disease, further validating its capability and scalability. Initial results support further development of the new concepts, representing another potential collaboration opportunity for us," says Birgitte Rønø, CSO of Evaxion.

Evaxion will also present data from its EVX-V1 program at the World Vaccine Congress. EVX-V1 targets Cytomegalovirus (CMV). AI-Immunology™ has discovered novel CMV antigens and EVX-V1 is a next-generation, multi-component vaccine program combining these novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens. This broader multi-targeted strategy is expected to strengthen the protective potential of the future vaccine.

**Presentations details:**

Presentation title: Designing a novel poliovirus vaccine using AI-Immunology™

Session: Emerging & re-emerging diseases

Location: Room 202A

Date/Time: April 1, 2026, at 16:40 ET&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

Presenter: Thomas Trolle, PhD, Director, Bioinformatics at Evaxion

Abstract title: AI-powered target discovery for a novel CMV vaccine

Session: Emerging & re-emerging Diseases

Location: Room 202A

Date/Time: April 2, 2026, at 10:25 ET

Presenter: Pär Comstedt, VP, Infectious disease vaccine development at Evaxion

**Contact information**

Evaxion A/S

Mads Kronborg

Vice President, Investor Relations & Communication

+45 53 54 82 96

mak@evaxion.ai

**About Evaxion**

Evaxion is a pioneering TechBio company based upon its proprietary, clinically validated and scalable AI platform, AI-Immunology™. The platform harnesses the power of artificial intelligence to decode the human immune system and develop novel vaccine candidates for cancer and infectious diseases.

With AI-Immunology™ we conduct rapid, efficient and high-quality target discovery, drug design and development. Our team of +40 experts covers the entire value chain from target discovery to clinical development

We have developed a clinical pipeline of both personalized and off-the-shelf cancer vaccine candidates as well as prophylactic vaccine candidates for infectious diseases. All our candidates address high unmet medical needs, reflecting our commitment to transforming patients' lives by providing innovative and targeted treatment options.

For more information about Evaxion, AI-Immunology™ and our pipeline, please visit our website.

**Forward-looking statement**

This announcement contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The words "target," "believe," "expect," "hope," "aim," "intend," "may," "might," "anticipate," "contemplate," "continue," "estimate," "plan," "potential," "predict," "project," "will," "can have," "likely," "should," "would," "could," and other words and terms of similar meaning identify forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including, but not limited to, risks related to: our financial condition and need for additional capital; our development work; cost and success of our product development activities and preclinical and clinical trials; commercializing any approved pharmaceutical product developed using our AI platform technology, including the rate and degree of market acceptance of our product candidates; our dependence on third parties including for conduct of clinical testing and product manufacture; our inability to enter into partnerships; government regulation; protection of our intellectual property rights; employee matters and managing growth; our ADSs and ordinary shares, the impact of international economic, political, legal, compliance, social and business factors, including inflation, and the effects on our business from other significant geopolitical and macro-economic events; and other uncertainties affecting our business operations and financial condition. For a further discussion of these risks, please refer to the risk factors included in our most recent Annual Report on Form 20-F and other filings with the US Securities and Exchange Commission (SEC), which are available at **www.sec.gov**. We do not assume any obligation to update any forward-looking statements except as required by law.